Armour Thyroid (thyroid tablets, USP)
Armour Thyroid tablets are pituitary thyroid-stimulating hormone suppressants used for the treatment of patients with thyroid cancer.
Allergen offers 1 financial assistance program for patients using Armour Thyroid:
Allergan Patient Assistance Program
Patients who are unable to afford the cost of Armour Thyroid tablets and meet other eligibility requirements are eligible for free medication. Eligible applicants will be enrolled for 12 months and a 90-day supply of medication will be shipped immediately to the physician. Medicare Part D applicants must have been denied the Low Income Subsidy and will only be enrolled until the end of the calendar year.
Caprelsa (vandetanib) Tablets
Caprelsa is a kinase inhibitor used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable, locally advanced or metastatic disease.
Caprelsa Access Support offers 3 financial assistance programs for patients using Caprelsa:
Caprelsa Co-Pay Assistance Program
Patients with private insurance whose out-of-pocket costs associated with Caprelsa are more than $50 may be eligible for assistance of up to $20,000 annually through this program.
Caprelsa Interim Access Program
This program provides a short-term supply of Caprelsa free of charge to patients with private insurance who are experiencing a delay in receiving coverage for this medication.
Sanofi Genzyme Patient Assistance Program
For eligible patients who are uninsured or underinsured, this program may provide Caprelsa free of charge.
Cometriq (cabozantinib)
Cometriq is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.
Exelixis offers 2 financial assistance programs for patients using Cometriq:
Exelixis Access Services Co-pay Assistance Program
This program helps with out-of-pocket costs for patients who have private insurance and meet the program’s eligibility requirements.
Exelixis Access Services Patient Assistance Program
This program provides Cometriq free of charge to patients who do not have insurance coverage and who meet eligibility requirements.
Lenvima (lenvatinib)
Lenvima is a kinase inhibitor and single agent used for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
Eisai offers 2 financial assistance programs for patients using Lenvima:
Lenvima $0 Co-pay Program
Privately insured patients may be eligible for this program, which offers a $0 copay for each prescription, with a $40,000 annual limit.
Eisai Assistance Program
This program provides Lenvima at no cost to financially needy patients who meet program eligibility criteria.
Nexavar (sorafenib) Tablets
Nexavar is a kinase inhibitor used for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma, refractory to radioactive iodine treatment.
Bayer’s Resources for Expert Assistance and Care Helpline (REACH) offers 2 financial assistance programs for patients using Nexavar:
Nexavar $0 Co-Pay Program
With this program, patients with private insurance pay a $0 copay for Nexavar, and the program pays up to $25,000, with no monthly maximum.
REACH Patient Assistance Program
Uninsured or underinsured patients who are prescribed Nexavar should contact the REACH services counselor to possibly qualify for free medication.
Synthroid (levothyroxine sodium tablets, USP)
Synthroid is used as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
AbbVie offers 1 financial assistance program for patients using Synthroid:
AbbVie Patient Assistance Foundation
Patients without insurance and with limited income may qualify to receive free Synthroid. Patients enrolled in Medicare Part D or another insurance program may be eligible for assistance on an exception basis.
Thyrogen (thyrotropin alfa)
Thyrogen is used as an adjunctive diagnostic tool for testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy. Thyrogen is also used as an adjunctive treatment in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer.
ThyrogenONE offers 2 financial assistance programs for patients using Thyrogen:
Thyrogen Co-Pay Assistance Program
Privately insured patients with out-of-pocket costs exceeding $100 for each Thyrogen kit may be eligible for assistance. This program requires patients to pay $100 of their out-of-pocket costs, and Sanofi Genzyme will cover any additional out-of-pocket costs, up to $1,000 per calendar year.
Thyrogen Patient Assistance Program
Patients who are uninsured or underinsured may be eligible to receive up to 2 kits of Thyrogen per calendar year.
Tirosint (levothyroxine sodium)
Tirosint capsules work as pituitary thyrotropin-stimulating hormone suppression and are used for the treatment of patients with thyrotropin-dependent well-differentiated thyroid cancer, as an adjunct to surgery and radioiodine therapy.
Akrimax offers 2 financial assistance programs for patients using Tirosint:
Tirosint Savings Card
With this savings card, patients are responsible for the first $35 and will receive up to $35 off their out-of-pocket expenses. Insured and cash-paying patients are eligible for the savings card. Medicare and Medicaid patients are not eligible for the program.
Akrimax Patient Assistance Program
Patients who meet Akrimax’s income guidelines may be eligible to receive Tirosint for free. Qualifying patients are eligible for free medication for 1 year and must then reapply to the program.
Table. Drugs Prescribed for Thyroid Cancer
- Drug name (generic name)
- Drug company
- Indication
- Patient support services
- Armour Thyroid (thyroid tablets, USP)
- Allergan
- Thyroid cancer
- Allergan Patient Assistance Program
844-424-6727
- Caprelsa (vandetanib) Tablets
- Sanofi Genzyme
- Unresectable locally advanced or metastatic medullary thyroid cancer
- Caprelsa Co-Pay Assistance Program
800-367-4999
Caprelsa Interim Access Program
Sanofi Genzyme Patient Assistance Program
- Cometriq (cabozantinib)
- Exelixis
- Progressive, metastatic medullary thyroid cancer
- Exelixis Access Services Co-pay Assistance Program
855-253-3273
Patient Assistance Program
855-253-3273
- Lenvima (lenvatinib)
- Eisai
- Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer
- Lenvima $0 Co-pay Program
866-613-4724
Eisai Assistance Program
866-613-4724
- Nexavar (sorafenib) Tablets
- Bayer
- Locally recurrent or metastatic, progressive, differentiated thyroid cancer, refractory to radioactive iodine treatment
- Nexavar $0 Co-Pay Program
866-639-2827
REACH Patient Assistance Program
866-639-2827
- Synthroid (levothyroxine sodium tablets, USP)
- AbbVie
- Thyrotropin-dependent well-differentiated thyroid cancer, as adjunct to surgery and radioiodine therapy
- AbbVie Patient Assistance Foundation
800-222-6885
- Thyrogen (thyrotropin alfa)
- Sanofi Genzyme
- Adjunctive diagnostic tool for testing for well-differentiated thyroid cancer with previous thyroidectomy
Adjunct treatment for radioiodine ablation of thyroid tissue remnants, after thyroidectomy for well-differentiated thyroid cancer - Thyrogen Co-Pay Assistance Program
888-497-6436
Thyrogen Patient Assistance Program
888-497-6436
- Tirosint (levothyroxine sodium)
- Akrimax
- Thyrotropin-dependent well-differentiated thyroid cancer, as an adjunct to surgery and radioiodine therapy
- Tirosint Savings Card
908-372-0506
Akrimax Patient Assistance Program
855-856-6915